Timothy B Campbell
Overview
Explore the profile of Timothy B Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waldschmidt J, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, et al.
Blood Adv
. 2025 Jan;
9(5):1132-1136.
PMID: 39813623
No abstract available.
2.
McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell T, et al.
Adv Ther
. 2023 Aug;
40(10):4626-4638.
PMID: 37597153
Introduction: Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell...
3.
Lin Y, Raje N, Berdeja J, Siegel D, Jagannath S, Madduri D, et al.
Nat Med
. 2023 Aug;
29(9):2286-2294.
PMID: 37592106
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple...
4.
Delforge M, Otero P, Shah N, Moshkovich O, Braverman J, Dhanda D, et al.
Leuk Res
. 2023 Apr;
129:107074.
PMID: 37087950
Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa...
5.
Connarn J, Witjes H, van Zutphen-van Geffen M, de Greef R, Campbell T, Hege K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(11):1687-1697.
PMID: 36794354
Idecabtagene vicleucel (ide-cel; bb2121) is a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This...
6.
Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda D, et al.
Leuk Res
. 2022 Aug;
120:106921.
PMID: 35930999
Objective: To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the...
7.
Delforge M, Shah N, Miguel J, Braverman J, Dhanda D, Shi L, et al.
Blood Adv
. 2021 Dec;
6(4):1309-1318.
PMID: 34933328
Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the...
8.
Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell T, Facon T, et al.
Blood Adv
. 2021 Aug;
5(15):3016-3020.
PMID: 34351389
The recent emergence of anti-B-cell maturation antigen (BCMA) therapies holds great promise in multiple myeloma (MM). These include chimeric antigen receptor (CAR) T cells, bispecific antibodies, and antibody-drug conjugates. Their...
9.
Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S, et al.
N Engl J Med
. 2021 Feb;
384(8):705-716.
PMID: 33626253
Background: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with...
10.
Broxmeyer H, Capitano M, Campbell T, Hangoc G, Cooper S
Stem Cells Dev
. 2016 Mar;
25(8):575-85.
PMID: 26943017
Dipeptidyl peptidase 4 (DPP4)/CD26 truncates certain proteins, and this posttranslational modification can influence their activity. Truncated (T) colony-stimulating factors (CSFs) are decreased in potency for stimulating proliferation of hematopoietic progenitor...